Adil Daud, MD

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine

• 1987-1990
  Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
• 1990-1994
  Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
• 1994-1997
  Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
• 1997-2000
  Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2000-2001
  Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2001-2005
  Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
• 2006-2008
  Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
• 2006-2008
  Director, Moffitt Clinical Research Network
• 2008-2010
  Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
• 2010-present
  HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

• 1986
  Honors in Pediatrics, Government Medical College, Nagpur, India
• 2000
  Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
• 2005-2007
  Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
• 2007-2010
  Best Doctors in America Award, Castle Connolly

• Daud AI, Bumpus FM and Husain A. Selective expression of Angiotensin II receptors on atretic follicles in the rat ovary. Endocrinology.1988 Jun;122(6):2727-34.
• Bumpus FM, Pucell AG, Daud AI and Husain A. Angiotensin II: an intraovarian regulatory peptide. Am J Med Sci.1988 Apr;295(4):406-8.
• Daud AI, Bumpus FM and Husain A. Characterization of ACE containing follicles during the rat estrus cycle and effect of ACE inhibitors on Ovulation. Endocrinology. 1990 June; 126(6):2927-35.
• Daud AI, Bumpus FM and Husain A. Angiotensin II: Does it have a direct obligate role in ovulation? Science (Technical Comment) 1991 vol 245:870.
• Katz EB, Steinhelper MJ, Delcarpio J, DaudAI, Claycomb WC and Field LJ. Cardiomyocyte proliferation in mice expressing a-myosin heavy chain -SV-40 T antigen transgenes. Am J Physiol 1992 Jun;262 (6 Pt 2):H1867-76.
• Daud AI, Lanson N, Claycomb W and Field LJ. Identification of SV-40 T-antigen-associated proteins in cardiomyocytes from transgenic mice. Am J Physiol 1993 May; 264 (5 Pt 2):H1693-700.
• Kim KK, Soonpaa MH, Daud AI, Koh GY, Kim JS and Field LJ. Tumor Suppressor gene expression during normal and pathological myocardial growth. J Biol Chem. 1994; 269(36):22607-13.
• Kim KK*, Daud AI*, Wong SC, Pajak L, Tsai SC, Wang HW, Henzel W and Field LJ. Mouse RAD 50 Has limited epitopic homology to P53 and is expressed in the mouse myocardium. J Biol Chem. 1996 15;271(46):29255-64. (co-first authors)
• Soonpaa MH, Daud AI, Koh GY, Klug MG, Kim KK, Wang H and Field LJ. Potential approaches for Myocardial Regeneration. Ann N Y Acad Sci: 1995 Mar 27 pp 752:446-54.
• Chandrasekhar S, Kyeung K, Field LJ and Daud AI. Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytes. Cell Biol Int. 1999;23(4):299-306
• Daud AI, Münster PN and Spriggs DR. New Drugs in Gynecologic Cancer. Current Treatment Options in Oncology 2001, 1:119-128.
• Daud AI. Use of Ca-125 to define Progression of Ovarian Cancer in patients with persistent elevated levels. Women's Oncology Review. 2002;2:73-4
• Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud AI, Chang A, Kraker A, Jove R, and Yu H. Role of Activated Src and Stat3 Signaling in Melanoma Tumor Cell Growth. Oncogene 2002 Oct 10:21(46):7001-10.
• Aghajanian C, Soignet S, Dizon, DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud AI, and Spriggs DR. Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies. Clin Cancer Res 2002 8: 2505-2511.
• Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15;92(2):223-37.
• Naing A, Messina JL, Vrionis FR, Daud AI. Malignant Melanoma Arising from a Spinal Nerve Root: Unusual Primary Site. J Clin Oncol. 2004 Aug 1;22(15):3194-5.
• Riker AI, Sondak VK, Fishman M, Daud AI, Pilon Thomas S. Current Immunotherapy of Melanoma. Clinical and Applied Immunology Reviews 5 (2005) 111-132.
• Daud AI, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D, Phase II trial of Karenitecin in patients with malignant melanoma: Clinical and translational study. Clin Cancer Res. 2005 Apr 15;11(8):3009-16.
• Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN, Valproic Acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 1:65(9):3815-22.
• Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control. 2005 Oct;12(4):223-9.
• Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000
• Thompson P and Daud AI. Randomized, Placebo Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer. Women's Oncology Review. 5, 3 (2005) 169
• Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK and Daud AI. Overall and Progression Free Survival in Metastatic Melanoma: Analysis of a Single Institution Database. Cancer Control (2006) 13 (3) 1
• Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud AI and Heller R. Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model. Clin Cancer Res (2006) 12 (10) 3177-3183
• Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci. 2006 Jan 1;11:1-14.
• Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 1;12(15):4645-51.
• Homsi J, Kim LC, Munster PN, Chodkiewicz C and Daud AI. Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: an update Women's Oncology Review.6, September, vol 3 (2006) 127-36
• Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma. Ann Surg Oncol. 2006 Dec 30
• Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ Melanoma. J Natl Compr Canc Netw. 2006 Aug;4(7):666-84.
• Munster PN, Marchion D, Bicaku E, Schmitt M, Padilla B, Stauffer P, Garrett C, Chiappori A, Lush R, Sullivan D, and Daud AI. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study. J Clin Oncol 2007 May 20;25(15):1979-85
• Homsi J, Cubitt C, Daud AI .The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 Jan;11(1):91-100.
• Homsi J, Simon GR, Garrett CR, Springett GR, DeConti, R, Chiappori, A, Burton MK, Munster P, Chiappori A, , Stromatt S, Allievi C, Anguili P, Eisenfeld A, Sullivan DM Daud AI. Phase I Trial of poly L glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 1;13(19):5855-61.
• Messina J, Yu, H, Riker AR, Munster PN, Jove R, Daud AI. Increased Stat3 Activation in Melanoma but not in benign Melanocytic lesions. Cancer Control, 2008 July, 15(3) 196-201
• Zager JS, Daud AI. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control. 2008 Jul;15(3):192-4.
• Sondak VK and Daud AI. The Interferons. In Principles and Practice of Oncology. 8th edition. Editors, DeVita, VT, Lawrence TS and Rosenberg SA, 2008
• Homsi J, Munster PN and Daud AI. Rethinking Phase I Trials: Going Beyond Toxicity in Evaluating New Agents. ASCO 2007 Education Book
• Homsi J and Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007 Jul;14(3):285-94.
• Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. Phenotypic and functional analysis of DC and clinical outcome in patients with high risk melanoma treated with adjuvant GM-CSF. J Clin Oncol. 2008 Jul 1;26(19):3235-41
• Solit D, Osman I, Polsky D, Panageas K, Daud A, Goydos J, Teitcher J, Wolchok J, Germino F, Krown S, Coit D, Rosen N and Chapman P. Phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with metastatic melanoma. Clinical Cancer Research 2008 December 15;14(24):8302-7
• Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant R, Shevde L, Li W, Eschrich S, Daud AI, Ju J and Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics 2008, 1:13.
• Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Aug 6.
• Demeierre MF, Sabel MS, Margolin KA, Daud AI and Sondak VK. State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer. 2008 Sep 17;113(S7):1728-1743.
• Tolcher A, Mita A, Lewis L, Garrett CR, Till E, Daud A, Patnaik A, Papadapolous K, Takimoto C, Bartels P, Keating A and Antonia S. Phase I And Pharmacokinetic Study Of YM155, A Small Molecule Inhibitor Of Survivin. J Clin Oncol. 2008 Nov 10;26(32):5198-203.
• Daud AI, DeConti R, Andrews SM, Sondak VK, Riker AI and Heller R. First in Man Phase I trial of IL-12 plasmid Electroporation in patients With Malignant Melanoma. J Clin Oncol November 24, 2008, 15.6794
• Hauschild A, Agarwala S, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White J, Xia C, Patel K, Kirkwood J, and Keilholz U. Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination with Carboplatin and Paclitaxel as Second-Line Treatment in Patients with Unresectable Stage III or Stage IV Melanoma J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6
• Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Neuger A, Hausheer FA, Lush R, Sullivan DM and Munster PN. Potentiation of a Topoisomerase I inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clin Cancer Res. 2009 Apr 1;15(7):2479-87.
• Munster PN ,Marchion D, Lacevic M, Kim J, Centeno B, Daud AI, Neuger A, Minton SA and Sullivan DM Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues. Clin Cancer Res. 2009 Mar 24
• Homsi J, Cubbitt C, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL and Daud AI. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun;19(3):167-75
• Munster PN, Marchion D, Bicaku E, Schmitt M, Chiappori A, Lush R, Sullivan D, and Daud AI. Phase I trial of vorinostat and doxorubicin in solid tumor malignancies Br J Cancer. 2009 Oct 6;101(7):1044-50.
• Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2010 May 28.